# Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

> **NCT01061840** · PHASE1 · COMPLETED · sponsor: **Gradalis, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Ewings Sarcoma
- Non Small Cell Lung Cancer
- Liver Cancer

## Interventions

- **BIOLOGICAL:** Vigil™
- **BIOLOGICAL:** Vigil™
- **BIOLOGICAL:** Vigil™

## Key facts

- **NCT ID:** NCT01061840
- **Lead sponsor:** Gradalis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2018-12-06
- **Final completion:** 2019-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061840, "Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01061840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*